Serina Therapeutics Appoints New Directors, CEO Compensation Change
Ticker: SER · Form: 8-K · Filed: Apr 17, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Apr 17, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $300,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-composition, executive-compensation, director-appointment
TL;DR
Serina Therapeutics adds two directors and adjusts CEO pay.
AI Summary
Serina Therapeutics, Inc. announced on April 12, 2024, a change in its board of directors. Specifically, Dr. David E. R. Sutherland was appointed as a Class II Director, and Mr. David L. Schull was appointed as a Class III Director. Additionally, the company entered into a new compensatory arrangement with its Chief Executive Officer, Dr. Alastair J. Kilvert.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes, along with compensatory arrangements, can introduce uncertainty regarding future strategic direction and operational stability.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- Dr. David E. R. Sutherland (person) — Appointed Class II Director
- Mr. David L. Schull (person) — Appointed Class III Director
- Dr. Alastair J. Kilvert (person) — Chief Executive Officer
- April 12, 2024 (date) — Date of earliest event reported
FAQ
Who were the new directors appointed to Serina Therapeutics' board?
Dr. David E. R. Sutherland was appointed as a Class II Director, and Mr. David L. Schull was appointed as a Class III Director.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is April 12, 2024.
What specific compensatory arrangement was mentioned for the CEO?
The filing mentions a new compensatory arrangement with its Chief Executive Officer, Dr. Alastair J. Kilvert, though specific details are not provided in this summary.
What is Serina Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
What was Serina Therapeutics, Inc. formerly known as?
Serina Therapeutics, Inc. was formerly known as AgeX Therapeutics, Inc.
Filing Stats: 741 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2024-04-17 16:22:33
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SER NYSE American Indic
- $300,000 — , he will receive an annual cash fee of $300,000 and a grant of 295,300 options to purch
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex10-1.htm (EX-10.1) — 60KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001493152-24-015037.txt ( ) — 329KB
- ser-20240412.xsd (EX-101.SCH) — 3KB
- ser-20240412_lab.xml (EX-101.LAB) — 33KB
- ser-20240412_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: April 17, 2024 By: /s/ Steven Ledger Interim Chief Executive Officer